Stocks Industrials RPID
NASDAQ · IndustrialsRapid Micro Biosystems, Inc. (RPID)
Rapid Micro Biosystems, Inc. brought in $35.2M of revenue over the twelve months to June 30, 2026, up 16.1% from a year earlier. It posted a net loss of $51.2M. In fiscal 2025 capital spending exceeded operating cash flow by $31.9M. At June 30, 2026 it held $14.7M in cash against $19.1M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
Key facts about Rapid Micro Biosystems, Inc.
- Net worth
- Rapid Micro Biosystems, Inc. has a market value (market cap) of $35.6M at the latest share price, and shareholders' equity of $17.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $33.6M (+19.7% year on year), with a net loss of $47.1M. Over the 12 months to June 30, 2026: revenue $35.2M, net loss $51.2M.
- Cash flow
- In fiscal 2025 operations used $31.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 7, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Rapid Micro Biosystems, Inc.'s next report was expected around November 6, 2026 and is not on file with the SEC yet.
What Rapid Micro Biosystems, Inc. does
Rapid Micro Biosystems, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NASDAQ under the ticker RPID.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $33.6M | -$47.1M | -$1.05 | -$31.9M |
| 2024 | $28.1M | -$46.9M | -$1.08 | -$45.5M |
| 2023 | $22.5M | -$52.5M | -$1.22 | -$46.9M |
| 2022 | $17.1M | -$60.8M | -$1.43 | -$65.3M |
| 2021 | $23.2M | -$73.5M | -$3.94 | -$58.2M |
| 2021 | $16.1M | -$37.1M | -$126.11 | -$31.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RPID ranks in Industrials
Latest SEC filings
What Rapid Micro Biosystems, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 11% to $8.1M versus the same quarter last year; diluted EPS -$0.27 versus -$0.27.
- August 7, 2026
- May 29, 2026
- May 28, 2026
- May 19, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 11% to $8M versus the same quarter last year; diluted EPS -$0.31 versus -$0.26.
- May 13, 2026
Insider trades
What the people running Rapid Micro Biosystems, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 24, 2026 | Kollender Richard SDirector | Exercised options | 1,681 | $1.3K |
| July 24, 2026 | Kollender Richard SDirector | Exercised options | 1,827 | $1.4K |
| July 22, 2026 | Spignesi Robert G. Jr.PRESIDENT AND CEO, Director | Exercised options | 1,402 | $1.1K |
| May 29, 2026 | Wirtjes Sean MCHIEF FINANCIAL OFFICER | Received as pay | 12,787 | $25K |
| May 29, 2026 | Malloy KirkDirector | Received as pay | 12,787 | $25K |
| May 29, 2026 | Pei Melinda LitherlandDirector | Received as pay | 12,787 | $25K |
| May 29, 2026 | Spignesi Robert G. Jr.PRESIDENT AND CEO, Director | Received as pay | 12,787 | $25K |
| May 29, 2026 | Lowenstein IneseDirector | Received as pay | 12,787 | $25K |
Who owns RPID
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bain Capital Life Sciences Fund, L.P.13G, passive with 1 related filers | 16.76% | August 14, 2026 |
| Longitude Capital Partners II, LLC13G, passive with 5 related filers | 8.6% | May 15, 2026 |
| Armistice Capital, LLC13G, passive with 1 related filers | 7.29% | August 14, 2026 |
| Endeavour Medtech Growth II LP13G, passive with 2 related filers | 5.7% | February 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 34 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,434,560 | 0 |
| Armistice Capital, LLC | 3,328,000 | new |
| ABG-WTT Global Life Science Capital Partners GP Ltd | 1,848,296 | 0 |
| Vanguard Capital Management LLC | 982,034 | -460 |
| Evernest Financial Advisors, LLC | 506,000 | +73,490 |
| Advent International, L.P. | 379,794 | -172,583 |
| Essex Investment Management Co LLC | 362,696 | -521,235 |
| Millennium Management LLC | 236,599 | -46,681 |
| Geode Capital Management, LLC | 228,041 | -19,136 |
| Renaissance Technologies LLC | 212,101 | +85,484 |
| BlackRock, Inc. | 189,832 | +32,600 |
| Legato Capital Management LLC | 119,534 | -155,390 |
| Vanguard Fiduciary Trust Co | 110,484 | +772 |
| Dimensional Fund Advisors LP | 104,192 | +16,603 |
| State Street Corp | 93,874 | 0 |
| XTX Topco Ltd | 79,727 | +18,657 |
| Sei Investments Co | 66,869 | -217,947 |
| Northern Trust Corp | 42,106 | -6,173 |
| Algert Global LLC | 38,307 | +15,126 |
| Morgan Stanley | 27,587 | -1,620 |
Insiders
9 insiders reported holding 2,492,345 shares in total, about $1.8M at the last price.
| Holder | Shares |
|---|---|
| Spignesi Robert G. Jr.PRESIDENT AND CEO, Director | 1,191,973 |
| Wirtjes Sean MCHIEF FINANCIAL OFFICER | 568,981 |
| Wilson John J. AddingtonCHIEF OPERATING OFFICER | 316,762 |
| Kollender Richard SDirector | 133,826 |
| Pei Melinda LitherlandDirector | 100,687 |
| Lowenstein IneseDirector | 70,687 |
| Malloy KirkDirector | 60,687 |
| Ricciardi Natale SDirector | 29,442 |
| Bika DafniDirector | 19,300 |
Questions about RPID
What does Rapid Micro Biosystems, Inc. do?
Rapid Micro Biosystems, Inc. is a company in the Industrials sector, listed on NASDAQ as RPID. Its shares trade on NASDAQ under the ticker RPID.
What is Rapid Micro Biosystems, Inc.'s net worth?
Rapid Micro Biosystems, Inc. has a market value (market cap) of $35.6M at the latest share price, and shareholders' equity of $17.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Rapid Micro Biosystems, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $51.2M on revenue of $35.2M.
How much revenue does Rapid Micro Biosystems, Inc. make?
Over the twelve months to June 30, 2026 Rapid Micro Biosystems, Inc. reported revenue of $35.2M. That is 16.1% more than a year earlier.
When did Rapid Micro Biosystems, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from August 14, 2026.
When is Rapid Micro Biosystems, Inc.'s next earnings report?
Rapid Micro Biosystems, Inc.'s next report was expected around November 6, 2026 and is not on file with the SEC yet.
Similar companies
Compare RPID with
Follow RPID
Get an email when Rapid Micro Biosystems, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Rapid Micro Biosystems, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.